{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:16:42Z","timestamp":1784945802903,"version":"3.55.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeted degradation of extracellular proteins via endo-lysosomal pathways constitutes a promising therapeutic strategy by enabling irreversible target removal and potentially reducing systemic effects of antigen accumulation. In this study, we present a systematic approach for the design and evaluation of Biological Degraders (BioDegs) that leverage receptor-mediated uptake through triantennary N-acetylgalactosamine (TGN) induced activation of the asialoglycoprotein receptor (ASGPR). While this principle has been established, there is still a lack about molecular determinants that influence uptake efficiency. Using interleukin-6 (IL-6) and its soluble receptor (sIL-6R) as therapeutically relevant model antigens, we systematically compared a range of BioDeg formats, including full-length antibodies (siltuximab, tocilizumab), a VHH against IL-6, and an IL-6 binding decoy-receptor design, with respect to binding affinity, thermal stability, cellular uptake, lysosomal trafficking, and degradation efficiency in HepG2 cells. Our results demonstrate that combined properties of scaffold architecture and receptor engagement critically influence degradation outcomes. This work provides a comparative framework for BioDeg design and highlights key parameters for developing lysosome-targeting degraders for extracellular proteins.<\/jats:p>","DOI":"10.1038\/s42003-026-10001-9","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:16:19Z","timestamp":1775888179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glycan-based biological degraders targeting the cytokine immune axis"],"prefix":"10.1038","volume":"9","author":[{"given":"Michelle","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Kollenkirchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Rasoulinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M. S.","family":"Koellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Luzarowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"L\u00fcbbehusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5197-2286","authenticated-orcid":false,"given":"Aimo","family":"Kannt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0232-1612","authenticated-orcid":false,"given":"Schara","family":"Safarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"10001_CR1","doi-asserted-by":"crossref","unstructured":"Ryan, D. P. & Matthews, J. M. Protein\u2013protein interactions in human disease. Curr. Opin. Struct. Biol. 15, 441\u2013446 (2005).","DOI":"10.1016\/j.sbi.2005.06.001"},{"key":"10001_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-biochem-061516-044518","volume":"86","author":"FU Hartl","year":"2017","unstructured":"Hartl, F. U. Protein Misfolding Diseases. Annu Rev. Biochem. 86, 21\u201326 (2017).","journal-title":"Annu Rev. Biochem."},{"key":"10001_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","volume":"157","author":"P Chames","year":"2009","unstructured":"Chames, P., Van Regenmortel, M., Weiss, E. & Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220\u2013233 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"10001_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-41199-1_1","volume":"219","author":"EV Gurevich","year":"2014","unstructured":"Gurevich, E. V. & Gurevich, V. V. Therapeutic potential of small molecules and engineered proteins. Handb. Exp. Pharm. 219, 1\u201312 (2014).","journal-title":"Handb. Exp. Pharm."},{"key":"10001_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao, L., Zhao, J., Zhong, K., Tong, A. & Jia, D. A. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct. Target. Ther. 7, 113 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10001_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40259-022-00551-9","volume":"36","author":"J Madan","year":"2022","unstructured":"Madan, J. et al. PROTACs: current trends in protein degradation by proteolysis-targeting chimeras. BioDrugs 36, 609\u2013623 (2022).","journal-title":"BioDrugs"},{"key":"10001_CR7","doi-asserted-by":"publisher","first-page":"110712","DOI":"10.1016\/j.isci.2024.110712","volume":"27","author":"X Tan","year":"2024","unstructured":"Tan, X., Huang, Z., Pei, H., Jia, Z. & Zheng, J. Molecular glue-mediated targeted protein degradation: a novel strategy in small-molecule drug development. iScience 27, 110712 (2024).","journal-title":"iScience"},{"key":"10001_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF02705243","volume":"31","author":"D Nandi","year":"2006","unstructured":"Nandi, D., Tahiliani, P., Kumar, A. & Chandu, D. The ubiquitin-proteasome system. J. Biosci. 31, 137\u2013155 (2006).","journal-title":"J. Biosci."},{"key":"10001_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425\u2013479 (1998).","journal-title":"Annu. Rev. Biochem."},{"key":"10001_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","volume":"76","author":"D Takahashi","year":"2019","unstructured":"Takahashi, D. et al. AUTACs: cargo-specific degraders using selective autophagy. Mol. cell 76, 797\u2013810.e10 (2019).","journal-title":"Mol. cell"},{"key":"10001_CR11","doi-asserted-by":"publisher","first-page":"11192","DOI":"10.1039\/D3SC03600F","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Targeting mitochondrial degradation by chimeric autophagy-tethering compounds. Chem. Sci. 14, 11192\u201311202 (2023).","journal-title":"Chem. Sci."},{"key":"10001_CR12","first-page":"100004","volume":"1","author":"Y Ding","year":"2024","unstructured":"Ding, Y., Xing, D., Fei, Y., Luo, S. & Lu, B. Perspectives of autophagy-tethering compounds (ATTECs) in drug discovery. Medicine 1, 100004 (2024).","journal-title":"Medicine"},{"key":"10001_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/protein\/gzq009","volume":"23","author":"T Igawa","year":"2010","unstructured":"Igawa, T. et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng. Des. Sel. 23, 385\u2013392 (2010).","journal-title":"Protein Eng. Des. Sel."},{"key":"10001_CR14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","volume":"17","author":"G Ahn","year":"2021","unstructured":"Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937\u2013946 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"10001_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291\u2013297 (2020).","journal-title":"Nature"},{"key":"10001_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jconrel.2023.12.014","volume":"365","author":"C Gauthier","year":"2024","unstructured":"Gauthier, C. et al. Cation-independent mannose 6-phosphate receptor: from roles and functions to targeted therapies. J. Controlled Release 365, 759\u2013772 (2024).","journal-title":"J. Controlled Release"},{"key":"10001_CR17","doi-asserted-by":"publisher","first-page":"47205","DOI":"10.1074\/jbc.M208534200","volume":"277","author":"MK Hancock","year":"2002","unstructured":"Hancock, M. K., Yammani, R. D. & Dahms, N. M. Localization of the carbohydrate recognition sites of the insulin-like growth factor II\/mannose 6-phosphate receptor to domains 3 and 9 of the extracytoplasmic region. J. Biol. Chem. 277, 47205\u201347212 (2002).","journal-title":"J. Biol. Chem."},{"key":"10001_CR18","doi-asserted-by":"publisher","first-page":"38658","DOI":"10.1074\/jbc.M407474200","volume":"279","author":"ST Reddy","year":"2004","unstructured":"Reddy, S. T. et al. Identification of a low affinity mannose 6-phosphate-binding site in domain 5 of the cation-independent mannose 6-phosphate receptor. J. Biol. Chem. 279, 38658\u201338667 (2004).","journal-title":"J. Biol. Chem."},{"key":"10001_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/glycob\/cwv001","volume":"25","author":"LJ Olson","year":"2015","unstructured":"Olson, L. J. et al. Identification of a fourth mannose 6-phosphate binding site in the cation-independent mannose 6-phosphate receptor. Glycobiology 25, 591\u2013606 (2015).","journal-title":"Glycobiology"},{"key":"10001_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acs.bioconjchem.4c00512","volume":"36","author":"S Kim","year":"2025","unstructured":"Kim, S., Kang, J., An, D., Seo, J. & Oh, D.-B. Lysosome-targeting chimera using mannose-6-phosphate glycans derived from glyco-engineered yeast. Bioconjugate Chem. 36, 424\u2013436 (2025).","journal-title":"Bioconjugate Chem."},{"key":"10001_CR21","doi-asserted-by":"publisher","first-page":"10009","DOI":"10.1021\/bi00495a001","volume":"29","author":"M Spiess","year":"1990","unstructured":"Spiess, M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 29, 10009\u201310018 (1990).","journal-title":"Biochemistry"},{"key":"10001_CR22","doi-asserted-by":"publisher","first-page":"17125","DOI":"10.1073\/pnas.0508537102","volume":"102","author":"EI Park","year":"2005","unstructured":"Park, E. I., Mi, Y., Unverzagt, C., Gabius, H.-J. & Baenziger, J. U. The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc. Proc. Natl. Acad. Sci. USA 102, 17125\u201317129 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10001_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202218106","volume":"62","author":"Y Wu","year":"2023","unstructured":"Wu, Y. et al. Aptamer-LYTACs for targeted degradation of extracellular and membrane proteins. Angew. Chem. 62, e202218106 (2023).","journal-title":"Angew. Chem."},{"key":"10001_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2320053121","volume":"121","author":"JL Yang","year":"2024","unstructured":"Yang, J. L. et al. Directed evolution of genetically encoded LYTACs for cell-mediated delivery. Proc. Natl. Acad. Sci. USA 121, e2320053121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10001_CR25","doi-asserted-by":"publisher","first-page":"21831","DOI":"10.1021\/jacs.2c08367","volume":"144","author":"J Zheng","year":"2022","unstructured":"Zheng, J. et al. Bifunctional compounds as molecular degraders for integrin-facilitated targeted protein degradation. J. Am. Chem. Soc. 144, 21831\u201321836 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"10001_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300643","volume":"19","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y., Liao, Y., Zhao, Y. & Tang, W. Development of Integrin Targeting Chimeras (ITACs) for the lysosomal degradation of extracellular proteins. ChemMedChem. 19, e202300643 (2024).","journal-title":"ChemMedChem"},{"key":"10001_CR27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41586-024-07948-2","volume":"638","author":"B Huang","year":"2025","unstructured":"Huang, B. et al. Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature 638, 796\u2013804 (2025).","journal-title":"Nature"},{"key":"10001_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","volume":"13","author":"S Rose-John","year":"2017","unstructured":"Rose-John, S., Winthrop, K. & Calabrese, L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat. Rev. Rheumatol. 13, 399\u2013409 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"10001_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.187.4.461","volume":"187","author":"T Alonzi","year":"1998","unstructured":"Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis.  J. Exp. Med. 187, 461\u2013468 (1998).","journal-title":"J. Exp. Med."},{"key":"10001_CR30","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2020\/e1801","volume":"75","author":"J Ding","year":"2020","unstructured":"Ding, J. et al. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. Clinics 75, e1801 (2020).","journal-title":"Clinics"},{"key":"10001_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-3083.2006.01750.x","volume":"63","author":"J Scheller","year":"2006","unstructured":"Scheller, J., Ohnesorge, N. & Rose-John, S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand. J. Immunol. 63, 321\u2013329 (2006).","journal-title":"Scand. J. Immunol."},{"key":"10001_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10001_CR33","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1002\/art.24126","volume":"58","author":"M Fujimoto","year":"2008","unstructured":"Fujimoto, M. et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58, 3710\u20133719 (2008).","journal-title":"Arthritis Rheum."},{"key":"10001_CR34","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1093\/rheumatology\/kead416","volume":"62","author":"D Nepal","year":"2023","unstructured":"Nepal, D. & Gazeley, D. Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus. Rheumatology 62, 3804\u20133810 (2023).","journal-title":"Rheumatology"},{"key":"10001_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3899\/jrheum.120447","volume":"40","author":"RM Fleischmann","year":"2013","unstructured":"Fleischmann, R. M. et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.  J. Rheumatol. 40, 113\u2013126 (2013).","journal-title":"J. Rheumatol."},{"key":"10001_CR36","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516\u20131523 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"10001_CR37","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese, M. C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968\u20132980 (2008).","journal-title":"Arthritis Rheum."},{"key":"10001_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones, G. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69, 88\u201396 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"10001_CR39","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2169\/internalmedicine.46.6262","volume":"46","author":"M Matsuyama","year":"2007","unstructured":"Matsuyama, M. et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman\u2019s disease. Intern. Med. 46, 771\u2013774 (2007).","journal-title":"Intern. Med."},{"key":"10001_CR40","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","volume":"28","author":"F van Rhee","year":"2010","unstructured":"van Rhee, F. et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman\u2019s disease. J. Clin. Oncol. 28, 3701\u20133708 (2010).","journal-title":"J. Clin. Oncol."},{"key":"10001_CR41","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nm1013-1193","volume":"19","author":"SCP Williams","year":"2013","unstructured":"Williams, S. C. P. First IL-6-blocking drug nears approval for rare blood disorder. Nat. Med. 19, 1193 (2013).","journal-title":"Nat. Med."},{"key":"10001_CR42","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","volume":"13","author":"M Sheppard","year":"2017","unstructured":"Sheppard, M., Laskou, F., Stapleton, P. P., Hadavi, S. & Dasgupta, B. Tocilizumab (Actemra). Hum. Vaccines Immunother. 13, 1972\u20131988 (2017).","journal-title":"Hum. Vaccines Immunother."},{"key":"10001_CR43","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40265-018-0929-z","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb, Y. N. & Deeks, E. D. Sarilumab: a review in moderate to severe rheumatoid arthritis. Drugs 78, 929\u2013940 (2018).","journal-title":"Drugs"},{"key":"10001_CR44","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","volume":"46","author":"U Klotz","year":"2007","unstructured":"Klotz, U., Teml, A. & Schwab, M. Clinical pharmacokinetics and use of infliximab. Clin. Pharmacokinet. 46, 645\u2013660 (2007).","journal-title":"Clin. Pharmacokinet."},{"key":"10001_CR45","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds, G. M. et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921\u2013926 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"10001_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","volume":"2","author":"E Dhimolea","year":"2010","unstructured":"Dhimolea, E. Canakinumab. mAbs 2, 3\u201313 (2010).","journal-title":"mAbs"},{"key":"10001_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","volume":"75","author":"M Sanford","year":"2015","unstructured":"Sanford, M. & McKeage, K. Secukinumab: first global approval. Drugs 75, 329\u2013338 (2015).","journal-title":"Drugs"},{"key":"10001_CR48","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang, S., Tanaka, T., Narazaki, M. & Kishimoto, T. Targeting Interleukin-6 Signaling in Clinic. Immunity 50, 1007\u20131023 (2019).","journal-title":"Immunity"},{"key":"10001_CR49","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2021-150433","volume":"138","author":"J-F Rossi","year":"2021","unstructured":"Rossi, J.-F. et al. Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity. Blood 138, 4004 (2021).","journal-title":"Blood"},{"key":"10001_CR50","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-021-00764-4","volume":"6","author":"X Li","year":"2021","unstructured":"Li, X., Shao, M., Zeng, X., Qian, P. & Huang, H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct. Target Ther. 6, 367 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"10001_CR51","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"IB McInnes","year":"2015","unstructured":"McInnes, I. B. et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann. Rheum. Dis. 74, 694\u2013702 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"10001_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40259-023-00634-1","volume":"38","author":"AB Avci","year":"2024","unstructured":"Avci, A. B., Feist, E. & Burmester, G. R. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? BioDrugs 38, 61\u201371 (2024).","journal-title":"BioDrugs"},{"key":"10001_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2144\/000114347","volume":"59","author":"L Martin","year":"2015","unstructured":"Martin, L., Maschberger, M. & Breitsprecher, D. Thermal unfolding of antibodies with the prometheus NT.48. BioTechniques 59, 251\u2013251 (2015).","journal-title":"BioTechniques"},{"key":"10001_CR54","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1021\/jacsau.5c00193","volume":"5","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Characterizing the membrane assembly of ASGPR related to mediated endocytosis using TriGalNAc-probe-based super-resolution imaging. JACS Au. 5, 2246\u20132256 (2025).","journal-title":"JACS Au"},{"key":"10001_CR55","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1006\/jmbi.2000.3853","volume":"300","author":"M Meier","year":"2000","unstructured":"Meier, M., Bider, M. D., Malashkevich, V. N., Spiess, M. & Burkhard, P. Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J. Mol. Biol. 300, 857\u2013865 (2000).","journal-title":"J. Mol. Biol."},{"key":"10001_CR56","unstructured":"Kolkman, J. A., Hermans, G. & Hoogenboom, H. R. J. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling. Patent Application - WO2007104529A2. (2007)"},{"key":"10001_CR57","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949\u2013963 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10001_CR58","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai, J. M., Nowak, R. P., Ebert, B. L. & Fischer, E. S. Targeted protein degradation: from mechanisms to clinic. Nat. Rev. Mol. Cell Biol. 25, 740\u2013757 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10001_CR59","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1021\/acs.jmedchem.0c01689","volume":"64","author":"J Pei","year":"2021","unstructured":"Pei, J. et al. Targeting lysosomal degradation pathways: new strategies and techniques for drug discovery. J. Med. Chem. 64, 3493\u20133507 (2021).","journal-title":"J. Med. Chem."},{"key":"10001_CR60","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"10001_CR61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.autrev.2010.08.015","volume":"10","author":"LE Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz, L. E. et al. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun. Rev. 10, 38\u201342 (2010).","journal-title":"Autoimmun. Rev."},{"key":"10001_CR62","doi-asserted-by":"publisher","first-page":"e1001077","DOI":"10.1371\/journal.ppat.1001077","volume":"6","author":"MS Maddur","year":"2010","unstructured":"Maddur, M. S., Vani, J., Lacroix-Desmazes, S., Kaveri, S. & Bayry, J. Autoimmunity as a predisposition for infectious diseases. PLoS Pathog. 6, e1001077 (2010).","journal-title":"PLoS Pathog."},{"key":"10001_CR63","doi-asserted-by":"publisher","first-page":"263310552211148","DOI":"10.1177\/26331055221114817","volume":"17","author":"LM James","year":"2022","unstructured":"James, L. M. & Georgopoulos, A. P. At the root of 3 \u201clong\u201d diseases: persistent antigens inflicting chronic damage on the brain and other organs in gulf war illness, long-COVID-19, and chronic fatigue syndrome. Neurosci. Insights 17, 26331055221114817 (2022).","journal-title":"Neurosci. Insights"},{"key":"10001_CR64","doi-asserted-by":"publisher","first-page":"034002","DOI":"10.1088\/2057-1739\/aa7e86","volume":"3","author":"RJ Seager","year":"2017","unstructured":"Seager, R. J., Hajal, C., Spill, F., Kamm, R. D. & Zaman, M. H. Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. Converg. Sci. Phys. Oncol. 3, 034002 (2017).","journal-title":"Converg. Sci. Phys. Oncol."},{"key":"10001_CR65","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-024-01803-2","volume":"25","author":"R Kratchmarov","year":"2024","unstructured":"Kratchmarov, R. et al. TCF1-LEF1 co-expression identifies a multipotent progenitor cell (TH2-MPP) across human allergic diseases. Nat. Immunol. 25, 902\u2013915 (2024).","journal-title":"Nat. Immunol."},{"key":"10001_CR66","doi-asserted-by":"publisher","unstructured":"Kougentakis, C. et al. Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACs. Preprint at https:\/\/doi.org\/10.1101\/2025.01.12.632472 (2025).","DOI":"10.1101\/2025.01.12.632472"},{"key":"10001_CR67","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","volume":"108","author":"W Busse","year":"2001","unstructured":"Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184\u2013190 (2001).","journal-title":"J. Allergy Clin. Immunol."},{"key":"10001_CR68","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer, M. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 368, 924\u2013935 (2013).","journal-title":"N. Engl. J. Med."},{"key":"10001_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aar7388","volume":"11","author":"L Lamertz","year":"2018","unstructured":"Lamertz, L. et al. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses. Sci. Signal. 11, eaar7388 (2018).","journal-title":"Sci. Signal."},{"key":"10001_CR70","doi-asserted-by":"publisher","first-page":"37577","DOI":"10.1074\/jbc.M101786200","volume":"276","author":"PC Rensen","year":"2001","unstructured":"Rensen, P. C. et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J. Biol. Chem. 276, 37577\u201337584 (2001).","journal-title":"J. Biol. Chem."},{"key":"10001_CR71","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1021\/ja2104679","volume":"134","author":"SK Mamidyala","year":"2012","unstructured":"Mamidyala, S. K. et al. Glycomimetic ligands for the human asialoglycoprotein receptor. J. Am. Chem. Soc. 134, 1978\u20131981 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"10001_CR72","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1021\/jm00009a014","volume":"38","author":"EAL Biessen","year":"1995","unstructured":"Biessen, E. A. L. et al. Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor. J. Med. Chem. 38, 1538\u20131546 (1995).","journal-title":"J. Med. Chem."},{"key":"10001_CR73","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1021\/acscentsci.1c00146","volume":"7","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y., Teng, P., Montgomery, N. T., Li, X. & Tang, W. Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins. ACS Cent. Sci. 7, 499\u2013506 (2021).","journal-title":"ACS Cent. Sci."},{"key":"10001_CR74","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1021\/jacs.6b12964","volume":"139","author":"CA Sanhueza","year":"2017","unstructured":"Sanhueza, C. A. et al. Efficient liver targeting by polyvalent display of a compact ligand for the asialoglycoprotein receptor. J. Am. Chem. Soc. 139, 3528\u20133536 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"10001_CR75","unstructured":"Saulnier, M. G. et al. ASGPR-binding compounds for the degradation of extracellular proteins. Patent Application - US20240072809A1. (2023)"},{"key":"10001_CR76","unstructured":"Posters & Publications. Avilar Therapeutics https:\/\/avilar-tx.com\/our-science\/posters-publications\/."},{"key":"10001_CR77","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","volume":"25","author":"DP Bondeson","year":"2018","unstructured":"Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25, 78\u201387.e5 (2018).","journal-title":"Cell Chem. Biol."},{"key":"10001_CR78","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"key":"10001_CR79","doi-asserted-by":"publisher","first-page":"e1395127","DOI":"10.1080\/2162402X.2017.1395127","volume":"7","author":"RM Hoffmann","year":"2017","unstructured":"Hoffmann, R. M. et al. Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology 7, e1395127 (2017).","journal-title":"Oncoimmunology"},{"key":"10001_CR80","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","volume":"15","author":"DT Abdeldaim","year":"2023","unstructured":"Abdeldaim, D. T. & Schindowski, K. Fc-Engineered therapeutic antibodies: recent advances and future directions. Pharmaceutics 15, 2402 (2023).","journal-title":"Pharmaceutics"},{"key":"10001_CR81","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1021\/ja039915e","volume":"126","author":"H Mao","year":"2004","unstructured":"Mao, H., Hart, S. A., Schink, A. & Pollok, B. A. Sortase-mediated protein ligation:\u2009 a new method for protein engineering. J. Am. Chem. Soc. 126, 2670\u20132671 (2004).","journal-title":"J. Am. Chem. Soc."},{"key":"10001_CR82","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1021\/ja0604111","volume":"128","author":"C-W Lin","year":"2006","unstructured":"Lin, C.-W. & Ting, A. Y. Transglutaminase-catalyzed site-specific conjugation of small-molecule probes to proteins in vitro and on the surface of living cells. J. Am. Chem. Soc. 128, 4542\u20134543 (2006).","journal-title":"J. Am. Chem. Soc."},{"key":"10001_CR83","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/d41573-024-00103-6","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. Extracellular targeted protein degrader removes antibodies in first test in humans. Nat. Rev. Drug Discov. 23, 483\u2013486 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10001_CR84","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura, T. et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381, 2114\u20132124 (2019).","journal-title":"N. Engl. J. Med."},{"key":"10001_CR85","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.3390\/ijms22063048","volume":"22","author":"T Qi","year":"2021","unstructured":"Qi, T. & Cao, Y. In Translation: FcRn across the therapeutic spectrum. Int. J. Mol. Sci. 22, 3048 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"10001_CR86","unstructured":"RStudio Team. RStudio Integrated Development for R. RStudio, PBC, Boston. - References - Scientific Research Publishing. https:\/\/www.scirp.org\/reference\/referencespapers?referenceid=3542223. (2020)."},{"key":"10001_CR87","unstructured":"Data Analysis | Springer Nature Link. https:\/\/link.springer.com\/chapter\/10.1007\/978-3-319-24277-4_9."},{"key":"10001_CR88","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2818.2006.01706.x","volume":"224","author":"S Bolte","year":"2006","unstructured":"Bolte, S. & Cordeli\u00e8res, F. P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213\u2013232 (2006).","journal-title":"J. Microsc."},{"key":"10001_CR89","doi-asserted-by":"crossref","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013D553 (2025).","DOI":"10.1093\/nar\/gkae1011"},{"key":"10001_CR90","unstructured":"Created in BioRender. Safarian, S. https:\/\/BioRender.com\/dohdsnx. (2025)."},{"key":"10001_CR91","unstructured":"Created in BioRenderSafarian, S. https:\/\/BioRender.com\/bfvbs3q. (2025)."},{"key":"10001_CR92","unstructured":"Created in BioRenderSafarian, S. https:\/\/BioRender.com\/p1sccx0. (2025)."},{"key":"10001_CR93","doi-asserted-by":"crossref","unstructured":"Wang, M. et al. Structural insights into IL-6 signaling inhibition by therapeutic antibodies. Cell Rep. 43, 113819 (2024).","DOI":"10.1016\/j.celrep.2024.113819"},{"key":"10001_CR94","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1126\/science.1083901","volume":"300","author":"MJ Boulanger","year":"2003","unstructured":"Boulanger, M. J., Chow, D., Brevnova, E. E. & Garcia, K. C. Hexameric structure and assembly of the interleukin-6\/IL-6 alpha-receptor\/gp130 complex. Science 300, 2101\u20132104 (2003).","journal-title":"Science"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10001-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10001-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10001-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:03:49Z","timestamp":1776243829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10001-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10001"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10001-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7357847\/v1","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors M.S, T.K, A.E, S.R, A.K and S.S are inventors on a provisional patent application related to assays employed in this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"530"}}